656 related articles for article (PubMed ID: 29407764)
21. The interactive role of CB(1) and GABA(B) receptors in hippocampal synaptic plasticity in rats.
Nazari M; Komaki A; Karamian R; Shahidi S; Sarihi A; Asadbegi M
Brain Res Bull; 2016 Jan; 120():123-30. PubMed ID: 26611204
[TBL] [Abstract][Full Text] [Related]
22. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Martín-García E; Burokas A; Martín M; Berrendero F; Rubí B; Kiesselbach C; Heyne A; Gispert JD; Millán O; Maldonado R
J Neurochem; 2010 Mar; 112(5):1338-13351. PubMed ID: 20028452
[TBL] [Abstract][Full Text] [Related]
23. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
24. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
Bouaboula M; Perrachon S; Milligan L; Canat X; Rinaldi-Carmona M; Portier M; Barth F; Calandra B; Pecceu F; Lupker J; Maffrand JP; Le Fur G; Casellas P
J Biol Chem; 1997 Aug; 272(35):22330-9. PubMed ID: 9268384
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo pharmacological characterization of SSD114, a novel GABAB positive allosteric modulator.
Porcu A; Lobina C; Giunta D; Solinas M; Mugnaini C; Castelli MP
Eur J Pharmacol; 2016 Nov; 791():115-123. PubMed ID: 27578262
[TBL] [Abstract][Full Text] [Related]
26. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.
Shore DM; Baillie GL; Hurst DH; Navas F; Seltzman HH; Marcu JP; Abood ME; Ross RA; Reggio PH
J Biol Chem; 2014 Feb; 289(9):5828-45. PubMed ID: 24366865
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoid receptor agonist-stimulated [35S]guanosine triphosphate gammaS binding in the brain of C57BL/6 and DBA/2 mice.
Basavarajappa BS; Hungund BL
J Neurosci Res; 2001 May; 64(4):429-36. PubMed ID: 11340650
[TBL] [Abstract][Full Text] [Related]
28. C-terminal truncated cannabinoid receptor 1 coexpressed with G protein trimer in Sf9 cells exists in a precoupled state and shows constitutive activity.
Chillakuri CR; Reinhart C; Michel H
FEBS J; 2007 Dec; 274(23):6106-15. PubMed ID: 17986258
[TBL] [Abstract][Full Text] [Related]
29. Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition.
Wu HM; Yang YM; Kim SG
Mol Pharmacol; 2011 Nov; 80(5):859-69. PubMed ID: 21803969
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant.
Paquette JJ; Wang HY; Bakshi K; Olmstead MC
Behav Pharmacol; 2007 Dec; 18(8):767-76. PubMed ID: 17989514
[TBL] [Abstract][Full Text] [Related]
31. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.
Horswill JG; Bali U; Shaaban S; Keily JF; Jeevaratnam P; Babbs AJ; Reynet C; Wong Kai In P
Br J Pharmacol; 2007 Nov; 152(5):805-14. PubMed ID: 17592509
[TBL] [Abstract][Full Text] [Related]
32. Detection of cannabinoid CB1, adenosine A1, muscarinic acetylcholine, and GABA(B) receptor-dependent G protein activity in transducin-deactivated membranes and autoradiography sections of rat retina.
Savinainen JR; Laitinen JT
Cell Mol Neurobiol; 2004 Apr; 24(2):243-56. PubMed ID: 15176438
[TBL] [Abstract][Full Text] [Related]
33. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
[TBL] [Abstract][Full Text] [Related]
34. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.
De Luca MA; Castelli MP; Loi B; Porcu A; Martorelli M; Miliano C; Kellett K; Davidson C; Stair JL; Schifano F; Di Chiara G
Neuropharmacology; 2016 Jun; 105():630-638. PubMed ID: 26686391
[TBL] [Abstract][Full Text] [Related]
35. Influence of positive allosteric modulators on GABA(B) receptor coupling in rat brain: a scintillation proximity assay characterisation of G protein subtypes.
Mannoury la Cour C; Herbelles C; Pasteau V; de Nanteuil G; Millan MJ
J Neurochem; 2008 Apr; 105(2):308-23. PubMed ID: 18021295
[TBL] [Abstract][Full Text] [Related]
36. The G protein-coupled cannabinoid-1 (CB1) receptor of mammalian brain: inhibition by phthalate esters in vitro.
Bisset KM; Dhopeshwarkar AS; Liao C; Nicholson RA
Neurochem Int; 2011 Oct; 59(5):706-13. PubMed ID: 21763743
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological characterization of GABAB receptor subtypes assembled with auxiliary KCTD subunits.
Rajalu M; Fritzius T; Adelfinger L; Jacquier V; Besseyrias V; Gassmann M; Bettler B
Neuropharmacology; 2015 Jan; 88():145-54. PubMed ID: 25196734
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
39. The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity.
Turu G; Simon A; Gyombolai P; Szidonya L; Bagdy G; Lenkei Z; Hunyady L
J Biol Chem; 2007 Mar; 282(11):7753-7. PubMed ID: 17227758
[TBL] [Abstract][Full Text] [Related]
40. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
